EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro susceptibility profiles of Candida parapsilosis species complex subtypes from deep infections to nine antifungal drugs

Wei Zhang, Minghua Zhan, Na Wang, Jingjing Fan, Xuying Han, Caiqing Li, Jinlu Liu, Jia Li, Yongwang Hou, Xinsheng Wang, Zhihua Zhang

Journal of Medical Microbiology · 2023

DOI: 10.1099/jmm.0.001640 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Microbiology, 2023. Verfasst von Wei Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Laboratory, The First Affiliated Hospital of Hebei North University, No. 12, Changqing Road, Qiaoxi District, Zhangjiakou City, 075000, Hebe…. Hauptthemen laut MEDLINE: Antifungal Agents, Candida parapsilosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hebei Province, Health Commission of Hebei Province, Zhangjiakou Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The Candida parapsilosis complex can be divided into C. parapsilosis sensu stricto , C. orthopsilosis , and C. metapsilosis subtypes. It is uncommon for drug sensitivity tests to type them. Gap Statement. In routine susceptibility reports, drug susceptibility of C. parapsilosis complex subtypes is lacking.

Aim

The aim of this study is to investigate the antifungal susceptibility and clinical distribution characteristics of the C. parapsilosis complex subtypes causing deep infection in patients. Methodology. Non-repetitive strains of C. parapsilosis complex isolated from deep infection from 2017 to 2019 were collected. Species-level identification was performed using a matrix-assisted laser desorption/ionization time-of-flight mass spectrometer and confirmed using ITS gene sequencing, when necessary. Antifungal susceptibility testing was performed using the Sensititre YeastOne system method.

Results

A total of 244 cases were included in the study, including 176 males (72.13 %, 60.69±13.43 years) and 68 females (27.87 %, 60.21±10.59 years). The primary diseases were cancer (43.44 %), cardiovascular disease (25.00 %), digestive system diseases, (18.44 %), infection (6.97 %), and nephropathy (6.15 %). Strains were isolated from the bloodstream (63.11 %), central venous catheters (15.16 %), pus (6.56 %), ascites (5.74 %), sterile body fluid (5.33 %), and bronchoalveolar lavage fluid (BALF, 4.09 %). Of the 244 C. parapsilosis complex strains, 179 (73.26 %) were identified as C. parapsilosis sensu stricto , 62 (25.41 %) were C. orthopsilosis , and three (1.23 %) were C. metapsilosis . Only one C. parapsilosis sensu stricto strain was resistant to anidulafungin, micafungin, caspofungin, and voriconazole, and it was non-wild-type (NWT) to amphotericin B. Furthermore, six C. parapsilosis sensu stricto strains were resistant to fluconazole, and one was dose-dependent susceptible. Five C. parapsilosis sensu stricto strains were NWT to posaconazole. Only one C. orthopsilosis strain was NWT for anidulafungin, micafungin, caspofungin, fluconazole, voriconazole, amphotericin B, and posaconazole, while the rest of the strains were wild-type.

Conclusion

C. parapsilosis sensu stricto was the main clinical isolate from the C. parapsilosis complex in our hospital. Most strains were isolated from the bloodstream. The susceptibility rate to commonly used antifungal drugs was more than 96 %. Furthermore, most of the infected patients were elderly male cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsCandida parapsilosisFemaleHumansMaleAgedFluconazoleCandidaAmphotericin BVoriconazoleCaspofunginMicafunginAnidulafunginMicrobial Sensitivity TestsDrug Resistance, Fungal

Stichwörter der Autor:innen

Candida parapsilosiscomplexazolesdrug resistanceechinocandinswild type

Substanzen

Antifungal AgentsFluconazoleAmphotericin BVoriconazoleCaspofunginMicafunginAnidulafungin

Autor:innen und Institutionen

  • Clinical Laboratory, The First Affiliated Hospital of Hebei North University, No. 12, Changqing Road, Qiaoxi District, Zhangjiakou City, 075000, Hebei Province, PR China.
  • Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, PR China, Beijing, 100730.
  • Clinical Laboratory Diagnostics, Peking University People's Hospital, 11 Xizhimen South Street, Beijing, 100044, PR China.
  • Infectious Disease Department, The First Affiliated Hospital of Hebei North University, No. 12, 15 Changqing Road, Qiaoxi District, Zhangjiakou City, 075000, Hebei Province, PR China.
  • Respiratory and Critical Care Medicine Intensive Care Unit, The First Affiliated Hospital of Hebei North University, No. 12, Changqing Road, Qiaoxi District, Zhangjiakou City, 075000, Hebei Province, PR China.

Förderung

  • Natural Science Foundation of Hebei Province
  • Health Commission of Hebei Province
  • Zhangjiakou Science and Technology Bureau

Zitieren

APA

Zhang, W., Zhan, M., Wang, N., Fan, J., Han, X., Li, C., Liu, J., Li, J., Hou, Y., Wang, X., & Zhang, Z. (2023). In vitro susceptibility profiles of Candida parapsilosis species complex subtypes from deep infections to nine antifungal drugs. Journal of Medical Microbiology. https://doi.org/10.1099/jmm.0.001640

Vancouver

Zhang W, Zhan M, Wang N, Fan J, Han X, Li C, et al. In vitro susceptibility profiles of Candida parapsilosis species complex subtypes from deep infections to nine antifungal drugs. Journal of Medical Microbiology. 2023. doi:10.1099/jmm.0.001640

BibTeX
@article{Zhang2023,
  author = {Zhang, Wei and Zhan, Minghua and Wang, Na and Fan, Jingjing and Han, Xuying and Li, Caiqing and Liu, Jinlu and Li, Jia and Hou, Yongwang and Wang, Xinsheng and Zhang, Zhihua},
  title = {In vitro susceptibility profiles of Candida parapsilosis species complex subtypes from deep infections to nine antifungal drugs},
  journal = {Journal of Medical Microbiology},
  year = {2023},
  doi = {10.1099/jmm.0.001640}
}
Kostenlos starten →